SERD Therapeutics Market Outlook Highlighting Key Players, Competitive Landscape, and Emerging Treatment Options

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global SERD Therapeutics Market- by Products (Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859 and Other Generics), Therapy (First-Line Treatment and Second-Line Treatment), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by Insight Analytics, the global SERD Therapeutics market was valued at USD 1339.0 Mn in 2024. It is expected to reach USD 2108.7 Mn by the year 2034, with a CAGR of 4.8 % during a forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1246

Selective estrogen receptor degraders (SERDs) represent a class of therapeutic agents designed to inhibit estrogen receptors, primarily employed in the management of estrogen receptor-positive (ER+) breast cancer. These therapies can be administered either as standalone treatments or in combination with other therapeutic modalities. Although SERDs are gaining traction in clinical practice, their full therapeutic potential in breast cancer treatment remains underexplored, offering considerable opportunities for innovation and expanded research.

The global SERD therapeutics market is projected to experience significant growth driven by several critical factors. These include the rising incidence and mortality rates of breast cancer, an increasing number of relapsed and treatment-resistant cases, and the limitations of existing hormone receptor-targeted therapies in effectively managing metastatic breast cancer. Furthermore, heightened investments in research and development by leading pharmaceutical companies, advancements in drug delivery and dosing technologies, and growing government support through funding initiatives are contributing to market expansion.

Additionally, there is a growing demand for effective endocrine therapies that manage chronic conditions while improving patient quality of life. The market is also expected to benefit from the need for more accessible, minimally invasive treatment options and enhanced therapeutic outcomes, particularly in scenarios where current treatments are inadequate. Collectively, these factors highlight significant prospects for innovation and commercial growth within the SERD therapeutics sector.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

North America is anticipated to contribute to the SERD Therapeutics market over the years. The demand for North American SERD treatments is expanding due to rising breast cancer incidence, recurrence from current endocrine therapy, and extensive research and development in the area. In addition, the Asia Pacific SERD Therapeutics market is expected to grow significantly during the forecast period. The market is anticipated to be driven by the rising focus of the leading players on research and development (R&D) activity for new product introduction, as well as the increased usage of SERDs as a combination therapy with other endocrine drugs. Additional factors driving the expansion include increased public and private funding for SERD therapy's improved outcomes and safety.

Major market players operating in the SERD Therapeutics market include
Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC. and Zentalis Pharmaceuticals.

Recent collaborations and agreements in the market:
• In June 2021, Verzenio® (abemaciclib), an investigational treatment for high-risk early breast cancer, and its oral selective estrogen receptor degrader (SERD) LY3484356 both saw fresh results from Eli Lilly and Company (ASCO). An exploratory analysis from the successful Phase 3 monarch research investigating the CDK4/6 inhibitor Verzenio in a subpopulation of patients with HR+, HER2-, high-risk early breast cancer (EBC) who had received neoadjuvant chemotherapy is being made public by Lilly.
• In September 2019, G1 Therapeutics, Inc. reported preliminary findings from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in people with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. In the trial, G1T48 was well tolerated and showed anti-tumor activity in patients who had received a significant amount of pretreatment. As a result of the trial's positive findings, G1T48 will likely be developed further for use as both a first-line treatment and an adjuvant, and a first-line Phase 3 pivotal trial is anticipated to start in 2020.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1246

Market Segments
Global SERD Therapeutics Market, by Products, 2022-2030 (Value US$ Mn)
• Faslodex
• RAD1901
• GDC-9545
• AZD9833
• SAR439859
• Other Generics
Global SERD Therapeutics Market, by Therapy, 2022-2030 (Value US$ Mn)
• First-Line Treatment
• Second-Line Treatment
Global SERD Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America SERD Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe SERD Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific SERD Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America SERD Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa SERD Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global SERD Therapeutics market
 To receive an industry overview and future trends in the SERD Therapeutics market
 To analyze the SERD Therapeutics market drivers and challenges
 To get information on the SERD Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the SERD Therapeutics market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-serd-therapeutics-market/1246

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.